Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT04077736
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT04077684
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04062006
Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04062019
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2024-06-12
- Target Recruit Count
- 9
- Registration Number
- NCT04052334
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
FT516 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT04023071
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 6
- Registration Number
- NCT03992326
- Locations
- 🇨🇭
CHUV Oncology Department, Lausanne, Vaud, Switzerland
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 8
- Registration Number
- NCT03912831
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
- Target Recruit Count
- 30
- Registration Number
- NCT03891706
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, gaungdong, China
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 37
- Registration Number
- NCT03841110
- Locations
- 🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.